| |
Severe hypoglycemia |
Symptomatic hypoglycemia |
| |
IR (95% CI) |
IRR (95% CI) |
IR (95% CI) |
IRR (95% CI) |
| Overall |
0.09
(0.08-0.11) |
- |
9.26
(8.81-9.73) |
- |
| By gender |
|
|
|
|
| M |
0.06
(0.05-0.08) |
0.46
(0.35-0.62) |
7.77
(7.22-8.35) |
0.70
(0.63-0.77) |
| F |
0.14
(0.12-0.16) |
1.00
(RC) |
11.08
(10.35-11.86) |
1.00
(RC) |
| By age classes |
|
|
|
|
| <65 |
0.07
(0.05-0.09) |
1.00
(RC) |
8.91
(8.24-9.63) |
1.00
(RC) |
| 65-74 |
0.10
(0.08-0.13) |
1.50
(1.07-2.11) |
9.23
(8.52-10.00) |
1.04
(0.93-1.16) |
| >=75 |
0.15
(0.12-0.20) |
2.30
(1.60-3.31) |
9.89
(8.85-11.05) |
1.11
(0.97-1.27) |
| By diabetes duration |
|
|
|
|
| <=2 |
0.02
(0.01-0.05) |
1.00
(RC) |
4.63
(3.75-5.72) |
1.00
(RC) |
| 2-5 |
0.08
(0.06-0.12) |
3.66
(1.42-9.47) |
6.63
(5.76-7.63) |
1.43
(1.11-1.85) |
| 5.1-10 |
0.06
(0.04-0.09) |
2.66
(1.03-6.88) |
7.38
(6.59-8.27) |
1.60
(1.26-2.03) |
| >10 |
0.14
(0.12-0.17) |
6.30
(2.58-15.38) |
11.90
(11.15-12.69) |
2.57
(2.06-3.21) |
| By cardiac/cerebrovascular disease |
|
|
|
|
| NO |
0.10
(0.09-0.12) |
1.16
(0.79-1.70) |
8.7
(8.22-9.21) |
0.74
(0.65-0.83) |
| YES |
0.09
(0.06-0.12) |
1.00
(RC) |
11.83
(10.67-13.13) |
1.00
(RC) |
| By glucose lowering therapy schemes |
|
|
|
|
OHA (without
secretagogues) |
0.04
(0.03-0.06) |
1.00
(RC) |
5.57
(4.98-6.22) |
1.00
(RC) |
OHA (with
secretagogues) |
0.08
(0.06-0.11) |
2.00
(1.24-3.21) |
9.50
(8.64-10.45) |
1.71
(1.48-1.98) |
Insulin
(basal oral) |
0.10
(0.06-0.17) |
2.49
(1.31-4.73) |
10.76
(9.01-12.85) |
1.93
(1.57-2.38) |
Insulin
(basal bolus) |
0.29
(0.23-0.35) |
6.91
(4.52-10.56) |
18.36
(16.79-20.08) |
3.30
(2.86-3.80) |
Insulin
(Other schemes) |
0.13
(0.08-0.19) |
3.02
(1.70-5.36) |
14.55
(12.64-16.75) |
2.61
(2.19-3.13) |
| Diet |
0 |
- |
1.60
(1.10-2.34) |
0.29
(0.19-0.43) |
OHA: Oral Hypoglycemic Agents
RC: Reference Class
IR: Incidence Rate
95% CI: 95% Confidence Interval
IRR: Incidence Rate Ratio |
